Vaccine Stocks List

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$67.08
+0.1%
$71.68
$65.90
$87.86
$83.52B0.197.32 million shs8.46 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$108.85
+0.9%
$101.39
$62.55
$142.79
$41.68B1.624.12 million shs3.41 million shs
Novavax, Inc. stock logo
NVAX
Novavax
$4.15
-1.0%
$4.71
$3.53
$11.36
$580.79M1.597.50 million shs2.99 million shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$148.53
-0.7%
$155.83
$143.13
$175.97
$357.92B0.537.39 million shs9.60 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$26.26
-0.2%
$27.07
$25.23
$40.37
$148.70B0.6141.89 million shs24.50 million shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
+0.12%-0.42%-7.68%-15.72%-22.69%
Moderna, Inc. stock logo
MRNA
Moderna
+3.28%+3.95%+2.33%+6.71%-21.90%
Novavax, Inc. stock logo
NVAX
Novavax
+2.95%+5.01%-10.85%+3.46%-48.14%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
+0.30%+3.54%-3.65%-5.92%-8.63%
Pfizer Inc. stock logo
PFE
Pfizer
+0.23%+2.45%-3.80%-7.09%-34.05%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
4.9992 of 5 stars
4.23.04.24.13.02.53.8
Moderna, Inc. stock logo
MRNA
Moderna
4.0601 of 5 stars
3.12.00.04.62.43.30.6
Novavax, Inc. stock logo
NVAX
Novavax
3.8241 of 5 stars
3.53.00.04.71.40.80.6
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
4.9007 of 5 stars
3.23.04.23.93.02.51.9
Pfizer Inc. stock logo
PFE
Pfizer
4.995 of 5 stars
3.25.04.24.83.11.73.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2.27
Hold$84.5726.08% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.24
Hold$126.4916.20% Upside
Novavax, Inc. stock logo
NVAX
Novavax
3.00
Buy$17.00309.64% Upside
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.46
Hold$175.8618.40% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.38
Hold$36.3338.36% Upside

Current Analyst Ratings

Latest Vaccine Stocks Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/24/2024
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeReduce ➝ Hold$69.00
4/19/2024
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$105.00
4/18/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$169.00 ➝ $170.00
4/17/2024
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$81.00 ➝ $75.00
4/17/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$168.00 ➝ $167.00
4/17/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$180.00 ➝ $170.00
4/17/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$181.00 ➝ $175.00
4/15/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$215.00
4/15/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
4/11/2024
Moderna, Inc. stock logo
MRNA
Moderna
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold
4/9/2024
Moderna, Inc. stock logo
MRNA
Moderna
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$125.00
(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$27.12B3.08$8.97 per share7.48$18.26 per share3.67
Moderna, Inc. stock logo
MRNA
Moderna
$6.85B6.09N/AN/A$36.33 per share3.00
Novavax, Inc. stock logo
NVAX
Novavax
$983.71M0.59N/AN/A($6.04) per share-0.69
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$85.16B4.20$13.61 per share10.91$28.57 per share5.20
Pfizer Inc. stock logo
PFE
Pfizer
$58.50B2.54$2.98 per share8.82$15.81 per share1.66

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$5.67B$4.5014.919.160.9620.89%38.85%13.60%4/25/2024 (Confirmed)
Moderna, Inc. stock logo
MRNA
Moderna
-$4.71B-$12.41N/AN/AN/A-68.84%-10.23%-7.70%5/2/2024 (Confirmed)
Novavax, Inc. stock logo
NVAX
Novavax
-$545.06M-$5.53N/AN/AN/A-55.41%N/A-32.63%5/14/2024 (Estimated)
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$35.15B$16.049.2613.562.4645.26%36.43%15.01%7/18/2024 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$2.12B$0.3672.949.481.183.62%10.88%4.91%5/1/2024 (Confirmed)

Latest Vaccine Stocks Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/2/2024N/A
Moderna, Inc. stock logo
MRNA
Moderna
-$3.36N/A+$3.36N/AN/AN/A  
5/1/2024N/A
Pfizer Inc. stock logo
PFE
Pfizer
$0.57N/A-$0.57N/AN/AN/A  
4/25/2024N/A
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
-$1.1410N/A+$1.1410N/AN/AN/A  
4/16/2024Q1 24
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.64$2.71+$0.07$3.22$21.39 billion$21.38 billion    
2/28/2024Q4 2023
Novavax, Inc. stock logo
NVAX
Novavax
-$0.49-$1.44-$0.95-$1.44$310.96 million$291.34 million      
2/22/2024Q4 2023
Moderna, Inc. stock logo
MRNA
Moderna
-$0.78$0.55+$1.33$0.55$2.53 billion$2.80 billion    
2/6/2024Q4 23
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$1.76$1.72-$0.04$2.30$7.10 billion$7.12 billion    
1/30/202412/31/2023
Pfizer Inc. stock logo
PFE
Pfizer
-$0.19$0.10+$0.29$0.80$14.37 billion$14.25 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$3.084.59%+3.32%68.44%9 Years
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Novavax, Inc. stock logo
NVAX
Novavax
N/AN/AN/AN/AN/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$4.763.20%+5.70%29.68%63 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.686.40%+2.57%466.67%15 Years

Latest Vaccine Stocks Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/24/2024
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.426.4%5/10/20246/14/2024
4/16/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
quarterly$1.243.36%5/20/20245/21/20246/4/2024
2/1/2024
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Quarterly$0.774.14%3/14/20243/15/20243/28/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
1.08
1.43
1.27
Moderna, Inc. stock logo
MRNA
Moderna
0.04
3.42
3.36
Novavax, Inc. stock logo
NVAX
Novavax
N/A
0.70
0.67
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.38
1.16
0.91
Pfizer Inc. stock logo
PFE
Pfizer
0.69
0.91
0.69

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
83.67%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Novavax, Inc. stock logo
NVAX
Novavax
53.04%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
69.55%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
0.29%
Moderna, Inc. stock logo
MRNA
Moderna
15.20%
Novavax, Inc. stock logo
NVAX
Novavax
0.90%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.16%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
18,0001.25 billion1.24 billionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
5,600382.88 million324.68 millionOptionable
Novavax, Inc. stock logo
NVAX
Novavax
1,543139.95 million138.69 millionOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
131,9002.41 billion2.41 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
88,0005.66 billion5.66 billionOptionable

Vaccine Stocks Headlines

SourceHeadline
Pfizer Inc. (NYSE:PFE) Shares Sold by Alaska Permanent Fund CorpPfizer Inc. (NYSE:PFE) Shares Sold by Alaska Permanent Fund Corp
marketbeat.com - April 24 at 5:28 PM
Pfizer Inc. (NYSE:PFE) to Issue Quarterly Dividend of $0.42Pfizer Inc. (NYSE:PFE) to Issue Quarterly Dividend of $0.42
marketbeat.com - April 24 at 5:22 PM
Pfizer Declares Second-Quarter 2024 DividendPfizer Declares Second-Quarter 2024 Dividend
businesswire.com - April 24 at 4:37 PM
Pfizer (NYSE:PFE) Trading Down 0.5%Pfizer (NYSE:PFE) Trading Down 0.5%
marketbeat.com - April 24 at 4:22 PM
Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?
zacks.com - April 24 at 1:06 PM
Analysts Estimate Pfizer (PFE) to Report a Decline in Earnings: What to Look Out forAnalysts Estimate Pfizer (PFE) to Report a Decline in Earnings: What to Look Out for
zacks.com - April 24 at 11:06 AM
Pfizer gets grant for treatment of cancer using engineered immune cells targeting bcmaPfizer gets grant for treatment of cancer using engineered immune cells targeting bcma
pharmaceutical-technology.com - April 24 at 10:09 AM
6 of the Highest-Yielding S&P 500 Stocks Offer Huge Passive Income6 of the Highest-Yielding S&P 500 Stocks Offer Huge Passive Income
247wallst.com - April 24 at 7:30 AM
The Top 7 Dividend Stocks to Buy in 2024 to Build Lasting WealthThe Top 7 Dividend Stocks to Buy in 2024 to Build Lasting Wealth
investorplace.com - April 24 at 7:25 AM
Pfizer (PFE) Scheduled to Post Quarterly Earnings on WednesdayPfizer (PFE) Scheduled to Post Quarterly Earnings on Wednesday
americanbankingnews.com - April 24 at 1:58 AM
Pfizer’s Emblaveo receives European marketing approval for patients with multidrug-resistant infections and limited treatment optionsPfizer’s Emblaveo receives European marketing approval for patients with multidrug-resistant infections and limited treatment options
pharmabiz.com - April 24 at 12:08 AM
Pfizer confirms end of Boulder R&D operationsPfizer confirms end of Boulder R&D operations
msn.com - April 24 at 12:08 AM
Pfizer Inc. (NYSE:PFE) Shares Bought by South Dakota Investment CouncilPfizer Inc. (NYSE:PFE) Shares Bought by South Dakota Investment Council
marketbeat.com - April 23 at 8:58 PM
Pfizer to shutter Boulder R&D operationsPfizer to shutter Boulder R&D operations
bizwest.com - April 23 at 7:07 PM
3 Underappreciated Pharmaceutical Stocks to Buy Before They Surge3 Underappreciated Pharmaceutical Stocks to Buy Before They Surge
investorplace.com - April 23 at 3:00 PM
Pfizer (NYSE:PFE) Shares Up 0.5%Pfizer (NYSE:PFE) Shares Up 0.5%
marketbeat.com - April 23 at 2:58 PM
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Addus Homecare (ADUS), Pfizer (PFE) and Cardinal Health (CAH)Analysts’ Opinions Are Mixed on These Healthcare Stocks: Addus Homecare (ADUS), Pfizer (PFE) and Cardinal Health (CAH)
markets.businessinsider.com - April 23 at 2:03 PM
Better Buy: Pfizer vs. Viking TherapeuticsBetter Buy: Pfizer vs. Viking Therapeutics
fool.com - April 23 at 9:15 AM
Pfizer vs Moderna battle over COVID vaccine patents begins in UKPfizer vs Moderna battle over COVID vaccine patents begins in UK
finance.yahoo.com - April 23 at 7:37 AM
Pfizer vs Moderna battle over COVID vaccine patents begins in UKPfizer vs Moderna battle over COVID vaccine patents begins in UK
reuters.com - April 23 at 7:21 AM
New York State Common Retirement Fund Has $281.24 Million Position in Pfizer Inc. (NYSE:PFE)New York State Common Retirement Fund Has $281.24 Million Position in Pfizer Inc. (NYSE:PFE)
marketbeat.com - April 22 at 9:33 PM
Pfizer (PFE) Rises Higher Than Market: Key FactsPfizer (PFE) Rises Higher Than Market: Key Facts
zacks.com - April 22 at 6:51 PM
3 Blue-Chip Stocks That Will Beat Index Returns Over the Next 3 Years3 Blue-Chip Stocks That Will Beat Index Returns Over the Next 3 Years
investorplace.com - April 22 at 5:44 PM
EC approval for Pfizer’s Emblaveo in multidrug-resistant infectionsEC approval for Pfizer’s Emblaveo in multidrug-resistant infections
thepharmaletter.com - April 22 at 3:24 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Gilead Sciences logo

Gilead Sciences

NASDAQ:GILD
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
Moderna logo

Moderna

NASDAQ:MRNA
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Novavax logo

Novavax

NASDAQ:NVAX
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Johnson & Johnson logo

Johnson & Johnson

NYSE:JNJ
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Pfizer logo

Pfizer

NYSE:PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Are you interested in trading vaccine stocks?

Is it lucrative to invest in vaccine stocks? Learn more about your investment options and whether vaccine stocks deserve a place in your portfolio.

Learn more about vaccine stocks